SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ --
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report fourth quarter and year-end 2002 financial results after the
Nasdaq market closes today, Monday, February 3, 2003. Neurocrine will also
host a live Webcast to discuss its financial results and provide a company
update tomorrow morning, Tuesday, February 4, 2003 at 9:00 AM Eastern Standard
Time (EST) / 6:00 AM Pacific Standard Time (PST). Participants may access the
live Conference Call by dialing 1-800-245-3043 (U.S.) or 1-785-830-1959
(International). The call can also be accessed via the Webcast through the
Company's website at http://www.neurocrine.com or alternatively through a link
provided by PRNewswire at
http://www.firstcallevents.com/service/ajwz373451149gf12.html .
Gary A. Lyons, President and CEO of Neurocrine Biosciences and Paul W.
Hawran, Executive Vice President and CFO will present the financial results
for year-end 2002 and will discuss the Company's strategy in place for 2003.
In addition, other members of Neurocrine's senior management team will provide
an overview on Neurocrine's development program. If you are unable to attend
the Webcast and would like further information on this announcement please
contact Claudia Jones or Elizabeth Foster in the Investor Relations Department
at Neurocrine Biosciences at (858) 658-7600. A replay of the Conference Call
will be available by dialing 1-800-283-8486 (US) or 1-402-220-0869
(International) and will be archived until Tuesday, February 18, 2003.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, malignant brain tumors and peripheral
cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating
disorders, pain, stroke, and certain female health disorders. Neurocrine
Biosciences, Inc. news releases are available through the Company's website
via the Internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.
